SoylentNews

[AstraZeneca] expects that whole genomes, combined with individual health data, will reveal rare genetic variants that influence disease and suggest new drug targets.
[...]
Under the arrangement, [Human Longevity Inc.] will sequence an anticipated 500,000 samples from participants in AstraZeneca’s clinical trials, and share its own [26,000 complete genomes with corresponding clinical data].
[...]
The partnership also includes the University of Helsinki’s Institute for Molecular Medicine Finland, which will offer up for analysis thousands of sequenced genomes and samples from its biobank, accompanied by records compiled in the country’s healthcare system.